Scarica l'app Stockscreener
11.84
0.75%
-0.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Omeros Corp Borsa (OMER) Ultime notizie
H.C. Wainwright reiterates Omeros stock rating on rival trial miss By Investing.com - Investing.com Canada
Omeros Corp (OMER) Valuation: PE, PB & Fair Value Analysis - TradingKey
Omeros Corp (OMER) Institutional Confidence - TradingKey
Omeros Corp (OMER) Stock Jumps 12% After AstraZeneca Setback, Valuation Reflects Growth Uncertainty - GuruFocus
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights - Stocktwits
OMER | Omeros Corporation FinancialsIncome Statement - Quiver Quantitative
Omeros Corp (OMER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Omeros Corp (OMER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Form 4 Omeros Corporation For: 24 July By Investing.com - Investing.com South Africa
OMER|Omeros Corp|Price:11.340|Chg%:+1.550 - TradingKey
Omeros Corp (OMER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Omeros Corp (OMER) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - GlobeNewswire Inc.
OMER6080787 Bond Profile — Key Metrics - TradingView
Omeros repurchases $14.5M of 9.50% convertible notes, total retirements $30.5M - TradingView
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros CorporationOMER - PR Newswire
EMA Committee Rejects Marketing Authorization for Omeros Corp Antibody Narsoplimab - sekbernews.id
Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return - Yahoo Finance
Omeros Corporation Investigated by the Portnoy Law Firm - GlobeNewswire Inc.
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? - AOL.com
Omeros shares drop 19% after EMA rejects narsop... - Pluang
Omeros: Yartemlea Faces Headwinds While We Wait On Pipeline Developments - Seeking Alpha
Is Omeros Corporation (OMER) the Best Get Rich Quick Stock to Buy Right Now? - Insider Monkey
Omeros Corporation Files SEC Form 8-K for Other Events – Nasdaq: OMER, July 2026 - Minichart
Omeros to repurchase $16M of 9.50% notes, may buy up to $14.5M more - TradingView
Omeros (NASDAQ: OMER) expands 2029 note repurchases and weighs new debt - Stock Titan
Omeros Corporation Reports First Quarter 2026 Financial Results - The National Law Review
Omeros stock drops 19% after EU rejects key dru... - Pluang
OMEROS CORP (OMER) Stock Chart - ChartMill
Omeros stock crashes on regulatory setback: Buy the dip? - MSN
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
FDA Approved, Europe Unconvinced: Omeros' Stem Cell Transplant Treatment Hits Regulatory Divide - Sahm
Crude Oil Falls 4%; US Consumer Sentiment Rises In June - Sahm
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? - AOL.com
Omeros Corp (OMER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Omeros (OMER) Faces Regulatory Setback for Narsoplimab Approval - GuruFocus
Omeros stock crashes on regulatory setback: buy the dip? - Invezz
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):